Allogeneic hematopoietic stem cell transplantation for children and adolescents with acute myeloid leukemia in Brazil : a multicentric retrospective study
Main Author: | |
---|---|
Publication Date: | 2020 |
Other Authors: | , , , , , , , , , , , , , , |
Format: | Article |
Language: | eng |
Source: | Repositório Institucional da UFRGS |
Download full: | http://hdl.handle.net/10183/234531 |
Summary: | The survival rates of children with high-risk acute myeloid leukemia (AML) treated with hematopoietic stem cell transplant (HSCT) range from 60% to 70% in high-income countries. The corresponding rate for Brazilian children with AML who undergo HSCT is unknown. We conducted a retrospective analysis of 114 children with AML who underwent HSCT between 2008 and 2012 at institutions participating in the Brazilian Pediatric Bone Marrow Transplant Working Group. At transplant, 38% of the children were in first complete remission (CR1), 37% were in CR2, and 25% were in CR3þ or had persistent disease. The donors included 49 matched-related, 59 matched-unrelated, and six haploidentical donors. The most frequent source of cells was bone marrow (69%), followed by the umbilical cord (19%) and peripheral blood (12%). The 4-year overall survival was 47% (95% confidence interval [CI] 30%–57%), and the 4-year progression-free survival was 40% (95% CI 30%–49%). Relapse occurred in 49 patients, at a median of 122 days after HSCT. There were 65 deaths: 40 related to AML, 19 to infection, and six to graft versus host disease. In conclusion, our study suggests that HSCT outcomes for children with AML in CR1 or CR2 are acceptable and that this should be considered in the overall treatment planning for children with AML in Brazil. Therapeutic standardization through the adoption of multicentric protocols and appropriate supportive care treatment will have a significant impact on the results of HSCT for AML in Brazil and possibly in other countries with limited resources. |
id |
UFRGS-2_c4c8bf6bec2c4f195d8e029acf5b454f |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/234531 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Rodrigues, Ana Luiza de MeloBonfim, Carmem Maria SalesSeber, AdrianaColturato, Vergilio Antonio RensiZecchin, Victor GottardelloNichele, SamanthaDaudt, Liane EstevesFernandes, Juliana FolloniVieira, Ana karineDarrigo Junior, Luiz GuilhermeGomes, Alessandra AraujoArcuri, Leonardo JavierFarias, Luana Lenzi Emilio dePicharski, Gledson LuizRibeiro, Raul CorrêaFigueiredo, Bonald Cavalcante de2022-01-27T04:33:46Z20201555-3892http://hdl.handle.net/10183/234531001135976The survival rates of children with high-risk acute myeloid leukemia (AML) treated with hematopoietic stem cell transplant (HSCT) range from 60% to 70% in high-income countries. The corresponding rate for Brazilian children with AML who undergo HSCT is unknown. We conducted a retrospective analysis of 114 children with AML who underwent HSCT between 2008 and 2012 at institutions participating in the Brazilian Pediatric Bone Marrow Transplant Working Group. At transplant, 38% of the children were in first complete remission (CR1), 37% were in CR2, and 25% were in CR3þ or had persistent disease. The donors included 49 matched-related, 59 matched-unrelated, and six haploidentical donors. The most frequent source of cells was bone marrow (69%), followed by the umbilical cord (19%) and peripheral blood (12%). The 4-year overall survival was 47% (95% confidence interval [CI] 30%–57%), and the 4-year progression-free survival was 40% (95% CI 30%–49%). Relapse occurred in 49 patients, at a median of 122 days after HSCT. There were 65 deaths: 40 related to AML, 19 to infection, and six to graft versus host disease. In conclusion, our study suggests that HSCT outcomes for children with AML in CR1 or CR2 are acceptable and that this should be considered in the overall treatment planning for children with AML in Brazil. Therapeutic standardization through the adoption of multicentric protocols and appropriate supportive care treatment will have a significant impact on the results of HSCT for AML in Brazil and possibly in other countries with limited resources.application/pdfengCell transplantation. Elmsford. Vol. 29 (2020), 10 p.Leucemia mielóide agudaCriançaCélulas-tronco hematopoéticasTransplantesBrasilPediatric acute myeloid leukemia (AML)Hematopoietic stem cell transplant (HSCT)BrazilAllogeneic hematopoietic stem cell transplantation for children and adolescents with acute myeloid leukemia in Brazil : a multicentric retrospective studyEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001135976.pdf.txt001135976.pdf.txtExtracted Texttext/plain43393http://www.lume.ufrgs.br/bitstream/10183/234531/2/001135976.pdf.txtd1901ad2da341e639b3ef855101158bdMD52ORIGINAL001135976.pdfTexto completo (inglês)application/pdf314258http://www.lume.ufrgs.br/bitstream/10183/234531/1/001135976.pdf6563f35d3c019b1b3a6de12fdd92ec07MD5110183/2345312022-05-24 04:46:07.81112oai:www.lume.ufrgs.br:10183/234531Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2022-05-24T07:46:07Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Allogeneic hematopoietic stem cell transplantation for children and adolescents with acute myeloid leukemia in Brazil : a multicentric retrospective study |
title |
Allogeneic hematopoietic stem cell transplantation for children and adolescents with acute myeloid leukemia in Brazil : a multicentric retrospective study |
spellingShingle |
Allogeneic hematopoietic stem cell transplantation for children and adolescents with acute myeloid leukemia in Brazil : a multicentric retrospective study Rodrigues, Ana Luiza de Melo Leucemia mielóide aguda Criança Células-tronco hematopoéticas Transplantes Brasil Pediatric acute myeloid leukemia (AML) Hematopoietic stem cell transplant (HSCT) Brazil |
title_short |
Allogeneic hematopoietic stem cell transplantation for children and adolescents with acute myeloid leukemia in Brazil : a multicentric retrospective study |
title_full |
Allogeneic hematopoietic stem cell transplantation for children and adolescents with acute myeloid leukemia in Brazil : a multicentric retrospective study |
title_fullStr |
Allogeneic hematopoietic stem cell transplantation for children and adolescents with acute myeloid leukemia in Brazil : a multicentric retrospective study |
title_full_unstemmed |
Allogeneic hematopoietic stem cell transplantation for children and adolescents with acute myeloid leukemia in Brazil : a multicentric retrospective study |
title_sort |
Allogeneic hematopoietic stem cell transplantation for children and adolescents with acute myeloid leukemia in Brazil : a multicentric retrospective study |
author |
Rodrigues, Ana Luiza de Melo |
author_facet |
Rodrigues, Ana Luiza de Melo Bonfim, Carmem Maria Sales Seber, Adriana Colturato, Vergilio Antonio Rensi Zecchin, Victor Gottardello Nichele, Samantha Daudt, Liane Esteves Fernandes, Juliana Folloni Vieira, Ana karine Darrigo Junior, Luiz Guilherme Gomes, Alessandra Araujo Arcuri, Leonardo Javier Farias, Luana Lenzi Emilio de Picharski, Gledson Luiz Ribeiro, Raul Corrêa Figueiredo, Bonald Cavalcante de |
author_role |
author |
author2 |
Bonfim, Carmem Maria Sales Seber, Adriana Colturato, Vergilio Antonio Rensi Zecchin, Victor Gottardello Nichele, Samantha Daudt, Liane Esteves Fernandes, Juliana Folloni Vieira, Ana karine Darrigo Junior, Luiz Guilherme Gomes, Alessandra Araujo Arcuri, Leonardo Javier Farias, Luana Lenzi Emilio de Picharski, Gledson Luiz Ribeiro, Raul Corrêa Figueiredo, Bonald Cavalcante de |
author2_role |
author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Rodrigues, Ana Luiza de Melo Bonfim, Carmem Maria Sales Seber, Adriana Colturato, Vergilio Antonio Rensi Zecchin, Victor Gottardello Nichele, Samantha Daudt, Liane Esteves Fernandes, Juliana Folloni Vieira, Ana karine Darrigo Junior, Luiz Guilherme Gomes, Alessandra Araujo Arcuri, Leonardo Javier Farias, Luana Lenzi Emilio de Picharski, Gledson Luiz Ribeiro, Raul Corrêa Figueiredo, Bonald Cavalcante de |
dc.subject.por.fl_str_mv |
Leucemia mielóide aguda Criança Células-tronco hematopoéticas Transplantes Brasil |
topic |
Leucemia mielóide aguda Criança Células-tronco hematopoéticas Transplantes Brasil Pediatric acute myeloid leukemia (AML) Hematopoietic stem cell transplant (HSCT) Brazil |
dc.subject.eng.fl_str_mv |
Pediatric acute myeloid leukemia (AML) Hematopoietic stem cell transplant (HSCT) Brazil |
description |
The survival rates of children with high-risk acute myeloid leukemia (AML) treated with hematopoietic stem cell transplant (HSCT) range from 60% to 70% in high-income countries. The corresponding rate for Brazilian children with AML who undergo HSCT is unknown. We conducted a retrospective analysis of 114 children with AML who underwent HSCT between 2008 and 2012 at institutions participating in the Brazilian Pediatric Bone Marrow Transplant Working Group. At transplant, 38% of the children were in first complete remission (CR1), 37% were in CR2, and 25% were in CR3þ or had persistent disease. The donors included 49 matched-related, 59 matched-unrelated, and six haploidentical donors. The most frequent source of cells was bone marrow (69%), followed by the umbilical cord (19%) and peripheral blood (12%). The 4-year overall survival was 47% (95% confidence interval [CI] 30%–57%), and the 4-year progression-free survival was 40% (95% CI 30%–49%). Relapse occurred in 49 patients, at a median of 122 days after HSCT. There were 65 deaths: 40 related to AML, 19 to infection, and six to graft versus host disease. In conclusion, our study suggests that HSCT outcomes for children with AML in CR1 or CR2 are acceptable and that this should be considered in the overall treatment planning for children with AML in Brazil. Therapeutic standardization through the adoption of multicentric protocols and appropriate supportive care treatment will have a significant impact on the results of HSCT for AML in Brazil and possibly in other countries with limited resources. |
publishDate |
2020 |
dc.date.issued.fl_str_mv |
2020 |
dc.date.accessioned.fl_str_mv |
2022-01-27T04:33:46Z |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/234531 |
dc.identifier.issn.pt_BR.fl_str_mv |
1555-3892 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001135976 |
identifier_str_mv |
1555-3892 001135976 |
url |
http://hdl.handle.net/10183/234531 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Cell transplantation. Elmsford. Vol. 29 (2020), 10 p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/234531/2/001135976.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/234531/1/001135976.pdf |
bitstream.checksum.fl_str_mv |
d1901ad2da341e639b3ef855101158bd 6563f35d3c019b1b3a6de12fdd92ec07 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801225049634504704 |